Status:
RECRUITING
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
Lead Sponsor:
Mayo Clinic
Conditions:
Gastroesophageal Reflux
Regurgitation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Researchers hope to determine how often small intestinal bacterial overgrowth occurs after taking proton pump inhibitors.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Predominant symptoms of gastroesophageal reflux disease including heartburn, regurgitation
- Subjects must be able to give appropriate informed consent
- Exclusion criteria:
- Prior diagnosis of SIBO
- Use of PPIs or H2R-anatagonstists in the prior 3 months
- Major concomitant illness (renal, hepatic, rheumatologic or cardiovascular disease, or malignancy)
- Antibiotic therapy within one month
- Prior gastrointestinal surgery including esophageal, gastric, and small or large bowel surgery
- Previously diagnosed irritable bowel syndrome or inflammatory bowel disease
- Individuals who are pregnant or breast feeding
- Patients with plans to become pregnant
- Inability to take PPIs, including allergy/sensitivity
Exclusion
Key Trial Info
Start Date :
November 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05976165
Start Date
November 17 2023
End Date
January 31 2026
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224